CanSino DTcP vaccine

CanSino Biologics is developing an adsorbed diphtheria, tetanus, and acellular pertussis (DTcP) combined vaccine for the prevention of these three bacterial infections. Unlike traditional acellular pertussis vaccines that use co-purification, CanSino's formulation is component-based, meaning each pertussis antigen is individually purified and then combined in precise proportions. This method is designed to ensure batch-to-batch consistency and enhanced product stability. The vaccine is being developed in two primary forms: an infant DTcP vaccine and a Tdcp vaccine (with reduced antigen content) for adolescents and adults aged six years and older. The vaccine works by eliciting protective antibody responses against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, as well as against specific antigens of *Bordetella pertussis*.

Other names

DTcP vaccineTdcp vaccineabsorbed diphtheria, tetanus and acellular pertussis combined vaccineCanSino DTcPCanSino Tdcp